The future development of bevacizumab in colorectal cancerDIAZ-RUBIO, Eduardo; SCHMOLL, Hans-Joachim.Oncology. 2005, Vol 69, pp 34-45, issn 0030-2414, 12 p., SUP3Article

Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancerDIAZ-RUBIO, Eduardo; SCHMOLL, Hans-Joachim.Oncology. 2005, Vol 69, issn 0030-2414, 59 p., SUP3Serial Issue

Oxaliplatin: results in colorectal carcinomaCARRATO, Alfredo; GALLEGO, Javier; DIAZ-RUBIO, Eduardo et al.Critical reviews in oncology/hematology. 2002, Vol 44, Num 1, pp 29-44, issn 1040-8428, 16 p.Article

Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancerHURWITZ, Herbert; KABBINAVAR, Fairooz.Oncology. 2005, Vol 69, pp 17-24, issn 0030-2414, 8 p., SUP3Article

Irinotecan in the treatment of elderly patients with advanced colorectal cancerSASTRE, Javier; PUENTE, Javier; GARCFA-SAENZ, Jose A et al.Critical reviews in oncology/hematology. 2008, Vol 68, Num 3, pp 250-255, issn 1040-8428, 6 p.Article

Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancerCALDES, Trinidad; PEREZ-SEGURA, Pedro; TOSAR, Alicia et al.Teratogenesis, carcinogenesis, and mutagenesis. 2000, Vol 20, Num 5, pp 283-291, issn 0270-3211Article

Investigating the potential of bevacizumab in other indications : Metastatic renal cell, non- small cell lung, pancreatic and breast cancerDE GRAMONT, Aimery; VAN CUTSEM, Eric.Oncology. 2005, Vol 69, pp 46-56, issn 0030-2414, 11 p., SUP3Article

About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variantsGUTIERREZ-ENRIQUEZ, Sara; BONACHE, Sandra; MONTALBAN, Gemma et al.International journal of cancer (Print). 2014, Vol 134, Num 9, pp 2088-2097, issn 0020-7136, 10 p.Article

Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their originDE GARIBAY, Gorka Ruiz; GUTIERREZ-ENRIQUEZ, Sara; DIAZ-RUBIO, Eduardo et al.Breast cancer research and treatment. 2012, Vol 133, Num 1, pp 273-283, issn 0167-6806, 11 p.Article

Alternative Splicing and Molecular Characterization of Splice Site Variants: BRCA1 c.591C>T as a Case StudyDOSIL, Vanesa; TOSAR, Alicia; CANADAS, Carmen et al.Clinical chemistry (Baltimore, Md.). 2010, Vol 56, Num 1, pp 53-61, issn 0009-9147, 9 p.Article

MMP-7 and SGCE as distinctive molecular factors in sporadic colorectal cancers from the mutator phenotype pathwayORTEGA, Paloma; MORAN, Alberto; BENITO, Manuel et al.International journal of oncology. 2010, Vol 36, Num 5, pp 1209-1215, issn 1019-6439, 7 p.Article

XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancerCASSIDY, Jim; TABERNERO, Josep; SCHÖFFSKI, Patrick et al.Journal of clinical oncology. 2004, Vol 22, Num 11, pp 2084-2091, issn 0732-183X, 8 p.Article

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer familiesROMERO, Atocha; PEREZ-SEGURA, Pedro; TOSAR, Alicia et al.Breast cancer research and treatment. 2011, Vol 129, Num 3, pp 939-946, issn 0167-6806, 8 p.Article

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudySALTZ, Leonard B; CLARKE, Stephen; COUTURE, Felix et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 2013-2019, issn 0732-183X, 7 p.Article

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyVERMORKEN, Jan B; TRIGO, José; HITT, Ricardo et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2171-2177, issn 0732-183X, 7 p.Article

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer : Final report of the spanish cooperative group for the treatment of digestive tumors trialDIAZ-RUBIO, Eduardo; TABERNERO, Jose; MAUREL, Joan et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4224-4230, issn 0732-183X, 7 p.Article

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal CancerTABERNERO, Josep; VAN CUTSEM, Eric; SASTRE VALERA, Javier et al.Journal of clinical oncology. 2007, Vol 25, Num 33, pp 5225-5232, issn 0732-183X, 8 p.Article

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer : A Spanish cooperative group for the treatment of digestive tumors studySASTRE, Javier; MARCUELLO, Eugenio; MAESTU, Inmaculada et al.Journal of clinical oncology. 2005, Vol 23, Num 15, pp 3545-3551, issn 0732-183X, 7 p.Article

Prevalence of germline mutations of MLH and MSH2 in hereditary nonpolyposis colorectal cancer families from SpainCALDES, Trinidad; GODINO, Javier; DE LA HOYA, Miguel et al.International journal of cancer. 2002, Vol 98, Num 5, pp 774-779, issn 0020-7136Article

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriersMILNE, Roger L; OSORIO, Ana; BLANCO, Ignacio et al.Breast cancer research and treatment. 2010, Vol 119, Num 1, pp 221-232, issn 0167-6806, 12 p.Article

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo RegisterPUENTE, Javier; LOPEZ-TARRUELLA, Sara; LLOMBART, Antoni et al.Breast cancer research and treatment. 2010, Vol 122, Num 2, pp 591-600, issn 0167-6806, 10 p.Article

Circulating Tumor Cells in Metastatic Breast Cancer: Timing of Blood Extraction for AnalysisMARTIN, Miguel; ANGEL GARCIA-SAENZ, José; LOPEZ- TARRUELLA, Sara et al.Anticancer research. 2009, Vol 29, Num 10, pp 4185-4187, issn 0250-7005, 3 p.Article

Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: Clinical implicationsGONZALEZ-QUEVEDO, Rosa; GARCIA-ARANDA, Cristina; MORAN, Alberto et al.International journal of oncology. 2004, Vol 24, Num 2, pp 349-355, issn 1019-6439, 7 p.Article

Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or bothDE LA HOYA, Miguel; FERNANDEZ, Juan M; TOSAR, Alicia et al.JAMA, the journal of the American Medical Association. 2003, Vol 290, Num 7, pp 929-931, issn 0098-7484, 3 p.Article

Genomic organization of a novel glycosylphosphatidylinositol MAM gene expressed in human tissues and tumorsDE JUAN, Carmen; INIESTA, Pilar; GONZALEZ-QUEVEDO, Rosa et al.Oncogene (Basingstoke). 2002, Vol 21, Num 19, pp 3089-3094, issn 0950-9232Article